IQ Healthspan Wire https://iqhealthspan.com/news/ Longevity research, drug, trial and regulatory news from IQ Healthspan, checked against the primary sources. en-us Wed, 30 Sep 2026 12:00:00 +0000 FDA advisers back six peptides for compounding, reject DSIP https://iqhealthspan.com/news/fda-committee-recommends-six-peptides-for-compounding.html https://iqhealthspan.com/news/fda-committee-recommends-six-peptides-for-compounding.html Wed, 30 Sep 2026 12:00:00 +0000 An FDA advisory committee recommended BPC-157, KPV, TB-500, MOTS-C, Semax and Epitalon for the 503A compounding list on July 23–24, 2026, against FDA staff advice, and rejected DSIP. The votes are not binding. FDA advisory committee to weigh BPC-157 and TB-500 for legal compounding https://iqhealthspan.com/news/fda-peptide-compounding-advisory-july-2026.html https://iqhealthspan.com/news/fda-peptide-compounding-advisory-july-2026.html Tue, 16 Jun 2026 12:00:00 +0000 An FDA advisory committee will meet July 23–24, 2026 to review BPC-157, TB-500, MOTS-C, KPV, DSIP, Semax, and Epitalon for the 503A compounding list. Reclassification is not approval. Long-lived families show a head start that begins in childhood, not retirement https://iqhealthspan.com/news/exceptional-longevity-families-early-life-advantage.html https://iqhealthspan.com/news/exceptional-longevity-families-early-life-advantage.html Mon, 11 May 2026 12:00:00 +0000 A Danish national-registry study finds descendants of exceptionally long-lived families show measurable health and survival advantages early in life, suggesting FDA greenlights the first human trial of partial epigenetic reprogramming https://iqhealthspan.com/news/life-biosciences-er100-reprogramming-trial.html https://iqhealthspan.com/news/life-biosciences-er100-reprogramming-trial.html Thu, 30 Apr 2026 12:00:00 +0000 Life Biosciences' ER-100 has cleared FDA to begin the first targeted attempt at cellular age reversal in humans, starting with an eye disease indication. The tr FDA pilots real-time clinical trial monitoring with AstraZeneca and Amgen https://iqhealthspan.com/news/fda-real-time-clinical-trial-pilot.html https://iqhealthspan.com/news/fda-real-time-clinical-trial-pilot.html Tue, 28 Apr 2026 12:00:00 +0000 The FDA is testing continuous review of trial data, starting with two oncology programs. The model could materially shorten timelines for biomarker-heavy gerosc BioAge oral NLRP3 inhibitor cuts inflammation marker by 85% in Phase 1 https://iqhealthspan.com/news/bioage-bge102-nlrp3-inhibitor-phase1.html https://iqhealthspan.com/news/bioage-bge102-nlrp3-inhibitor-phase1.html Tue, 21 Apr 2026 12:00:00 +0000 BGE-102, an oral brain-penetrant NLRP3 inhibitor, dropped median hsCRP by at least 85% in obese adults with elevated inflammation. The drug was well-tolerated. A nasal spray quiets brain inflammation in aged mice — but "reversed aging" is the wrong headline https://iqhealthspan.com/news/intranasal-stem-cell-vesicles-brain-aging.html https://iqhealthspan.com/news/intranasal-stem-cell-vesicles-brain-aging.html Tue, 14 Apr 2026 12:00:00 +0000 An NIA-funded Texas A&M study used intranasal stem-cell-derived extracellular vesicles to reduce neuroinflammation and restore memory in aged mice. The mechanis A stealth biotech is pitching "brainless" human clones as a longevity solution. We think it's a bad detour. https://iqhealthspan.com/news/r3-biotechnologies-brainless-clone-controversy.html https://iqhealthspan.com/news/r3-biotechnologies-brainless-clone-controversy.html Mon, 30 Mar 2026 12:00:00 +0000 R3 Biotechnologies' bodyoid concept — decorticated human-like clones grown as transplant sources — was detailed in MIT Technology Review. We explain why the lon